Pacira | PCRX - Ebitda


Pacira reported $48.67M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Astellas Pharma JPY 235.24B 136.32B Jun/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
J&J USD 8.27B 1.08B Mar/2026
Ligand Pharmaceuticals USD -14.3M 81.08M Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novo Nordisk DKK 37.36B 2.64B Jun/2026
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 48.67M 8.43M Jun/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Supernus Pharmaceuticals USD 31.6M 2.37M Jun/2026
Teva Pharmaceutical Industries USD 474M 581M Jun/2026
Xeris Pharmaceuticals USD 12.33M 12.76M Mar/2026
Zoetis USD 939M 0 Mar/2026